CBS 2019
CBSMD教育中心
中 文

ASCVD Prevention

Abstract

Recommended Article

International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association Relationship Between Coronary Artery Calcium and Atherosclerosis Progression Among Patients With Suspected Coronary Artery Disease Non-obstructive High-Risk Plaques Increase the Risk of Future Culprit Lesions Comparable to Obstructive Plaques Without High-Risk Features: The ICONIC Study Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular DiseaseA Prespecified Analysis From the FOURIER Trial Autologous CD34+ Stem Cell Therapy Increases Coronary Flow Reserve and Reduces Angina in Patients With Coronary Microvascular Dysfunction The Objective Physical Activity and Cardiovascular Disease Health in Older Women (OPACH) Study Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial

Clinical Trial2021 Feb 16;143(7):673-684.

JOURNAL:Circulation. Article Link

Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial

TA Zelniker, M Ardissino, F Andreotti et al. Keywords: AF; AMI with atrial fibrillation and CHADS2 score ≥2; higher-dose edoxaban vs.lower-dose edoxaban regimen; warfarin; gender difference

Full Text PDF